DE69231927D1 - Methode zur behandlung des systemischen lupus erythematodes - Google Patents

Methode zur behandlung des systemischen lupus erythematodes

Info

Publication number
DE69231927D1
DE69231927D1 DE69231927T DE69231927T DE69231927D1 DE 69231927 D1 DE69231927 D1 DE 69231927D1 DE 69231927 T DE69231927 T DE 69231927T DE 69231927 T DE69231927 T DE 69231927T DE 69231927 D1 DE69231927 D1 DE 69231927D1
Authority
DE
Germany
Prior art keywords
systemic lupus
treating systemic
lupus erythematodes
treating
erythematodes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69231927T
Other languages
English (en)
Other versions
DE69231927T2 (de
Inventor
Marie Warner
Moore Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of DE69231927D1 publication Critical patent/DE69231927D1/de
Application granted granted Critical
Publication of DE69231927T2 publication Critical patent/DE69231927T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
DE69231927T 1991-02-22 1992-02-21 Methode zur behandlung des systemischen lupus erythematodes Expired - Fee Related DE69231927T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/660,470 US5078999A (en) 1991-02-22 1991-02-22 Method of treating systemic lupus erythematosus
PCT/US1992/001399 WO1992014477A1 (en) 1991-02-22 1992-02-21 Method of treating systemic lupus erythematosus

Publications (2)

Publication Number Publication Date
DE69231927D1 true DE69231927D1 (de) 2001-08-16
DE69231927T2 DE69231927T2 (de) 2001-11-22

Family

ID=24649665

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231927T Expired - Fee Related DE69231927T2 (de) 1991-02-22 1992-02-21 Methode zur behandlung des systemischen lupus erythematodes

Country Status (21)

Country Link
US (1) US5078999A (de)
EP (1) EP0572542B9 (de)
KR (1) KR100201517B1 (de)
AT (1) ATE202938T1 (de)
AU (1) AU664545B2 (de)
CA (1) CA2103568A1 (de)
CY (1) CY2305B1 (de)
DE (1) DE69231927T2 (de)
DK (1) DK0572542T3 (de)
ES (1) ES2157901T3 (de)
GR (1) GR3036477T3 (de)
HK (1) HK1011281A1 (de)
HU (1) HUT70489A (de)
IE (1) IE920556A1 (de)
IL (1) IL100904A (de)
MX (1) MX9200727A (de)
NZ (1) NZ241671A (de)
PT (1) PT100145B (de)
SG (1) SG52404A1 (de)
WO (1) WO1992014477A1 (de)
ZA (1) ZA921210B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5262424A (en) * 1992-02-18 1993-11-16 American Home Products Corporation Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
ES2089723T3 (es) 1992-03-27 1996-10-01 American Home Prod 29-demetoxirapamicina para inducir la inmunodepresion.
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5482945A (en) * 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
WO1994025022A1 (en) 1993-04-23 1994-11-10 Abbott Laboratories Rapamycin conjugates and antibodies
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US20010055593A1 (en) * 2000-03-14 2001-12-27 Joseph Sypek Use of rapamycin and agents that inhibit B7 activity in immunomodulation
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
WO2002024706A2 (en) 2000-09-19 2002-03-28 Wyeth Water soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
WO2003018574A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
JP2005501868A (ja) 2001-08-22 2005-01-20 ワイス ラパマイシン２９−エノール
MXPA05001013A (es) * 2002-07-30 2005-05-16 Wyeth Corp Formulaciones parentales que contienen un hidroxiester de rapamicina.
RU2326654C2 (ru) * 2002-09-17 2008-06-20 Уайт Пероральные композиции
ES2428354T3 (es) 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
AU2003301348A1 (en) * 2002-10-18 2004-05-04 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
CN102144961A (zh) * 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
EP1735321B1 (de) 2004-04-14 2008-10-08 Wyeth Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
WO2006086750A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CN101119709A (zh) * 2005-02-15 2008-02-06 惠氏公司 口服生物有效的cci-779配方
EA015922B1 (ru) 2005-11-14 2011-12-30 Ариад Фармасьютикалз, Инк. ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
EP2056821A2 (de) * 2006-08-22 2009-05-13 Novartis AG Rapamycin und seine derivate zur behandlung leberassoziierter fibrosierender erkrankungen
EP2702993B1 (de) 2006-09-13 2017-12-06 Elixir Medical Corporation Makrocyclische lactonverbindungen und verfahren zu deren verwendung
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
EP2352459A4 (de) * 2008-10-03 2013-09-25 Elixir Medical Corp Makrocyclische lactonverbindungen und verfahren zu ihrer verwendung
CN104042612A (zh) 2008-11-11 2014-09-17 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
KR20130128018A (ko) 2009-04-10 2013-11-25 하이얀 치 새로운 노화 방지 물질 및 그 확인 방법
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
EP2906214A1 (de) 2012-10-12 2015-08-19 The Board of Regents of The University of Texas System Verwendung von mtor-hemmern zur behandlung von vaskulären kognitiven störungen
EP2968281B1 (de) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor-hemmer zur vorbeugung von darmpolypenwachstum
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体

Also Published As

Publication number Publication date
CY2305B1 (en) 2003-07-04
AU1469192A (en) 1992-09-15
WO1992014477A1 (en) 1992-09-03
MX9200727A (es) 1992-09-01
HUT70489A (en) 1995-10-30
EP0572542A1 (de) 1993-12-08
HK1011281A1 (en) 1999-07-09
ES2157901T3 (es) 2001-09-01
NZ241671A (en) 1997-06-24
PT100145A (pt) 1993-08-31
US5078999A (en) 1992-01-07
EP0572542A4 (en) 1994-06-01
GR3036477T3 (en) 2001-11-30
EP0572542B1 (de) 2001-07-11
SG52404A1 (en) 1998-09-28
IL100904A (en) 1995-10-31
DE69231927T2 (de) 2001-11-22
ZA921210B (en) 1993-08-19
AU664545B2 (en) 1995-11-23
ATE202938T1 (de) 2001-07-15
DK0572542T3 (da) 2001-09-17
IL100904A0 (en) 1992-11-15
KR930703001A (ko) 1993-11-29
EP0572542B9 (de) 2001-11-21
IE920556A1 (en) 1992-08-26
PT100145B (pt) 1999-06-30
KR100201517B1 (ko) 1999-06-15
CA2103568A1 (en) 1992-08-23

Similar Documents

Publication Publication Date Title
DE69231927D1 (de) Methode zur behandlung des systemischen lupus erythematodes
EA199800104A1 (ru) Способ лечения диабета
WO2000035436A3 (en) Treatment of arthritis with mek inhibitors
ATE329911T1 (de) Fsh mimetika zur behandlung von infertilität
ID30062A (id) Alanog-analog benzopiran tersubstitusi untuk pengobatan radang
DK1105061T3 (da) Fremgangsmåde og apparat til rengöring af et endoskop
ES2172657T3 (es) Inhibidores de trombina.
NO983431L (no) Anti-klöemidler
DE69526311T2 (de) Verwendung von Rapamycin zur Behandlung von Anämie
DE69430257D1 (de) Intrastromaler, kornealer ring zur astigmatismuskorrektur
HUP0004271A2 (hu) Elhízás kezelésére szolgáló, amilint vagy amilin-agonistát tartalmazó készítmények
ATE288303T1 (de) Östrogen agonist-antagonist und testosteron enthaltende zusammensetzung zur behandlung abnehmender testosteronspiegel
EA199800764A1 (ru) Способ лечения или предупреждения макулярного отека или возрастной макулярной дистрофии
EA200300124A1 (ru) Применение прамипексола для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича
BR9808923B1 (pt) processos para fazer compostos inibidores de ciclooxigenase-2, e, compostos intermediÁrios para fazer inibidores de ciclooxigenase-2.
DE69114854D1 (de) Verfahren zur behandlung von photographischen abwässern.
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
DK0996727T3 (da) Obesitas-fænotypefremkaldende gen.
AR021749A1 (es) Uso de derivados de tiazolidinediona para el tratamiento o prevencion de cataratas.
DE69906729D1 (de) Zusammensetzung und methode zur behandlung von pseudomonas aeruginosa infektionen
EA200001105A1 (ru) 10-камфорсульфонат пароксетина для лечения нарушений цнс
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
DK1299102T3 (da) Anvendelse af riluzol eller salte deraf til forebyggelse og behandling af adrenoleukodystrofi
NO982487L (no) Gjenoppretting av eggehvitestoffer
ECSP993087A (es) Uso de derivados de tiazolidinediona para el tratamiento o prevencion de cataratas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WYETH (N.D.GES.D. STAATES DELAWARE), MADISON, N.J.

8339 Ceased/non-payment of the annual fee